恒瑞医药最新公告：9款药品首次纳入国家医保目录11款药品新增或续约成功

Group 1 - The company announced that 9 of its drugs have been included in the national medical insurance catalog for the first time, including injection of Rukang Qutuzumab and Apixaban Famitinib capsules [1] - Additionally, 11 drugs have either new indications or successful renewals, including injection of Carrelizumab and Fluorouracil capsules [1] - The total sales for these drugs are projected to be approximately 8.66 billion yuan for the year 2024 and about 7.55 billion yuan for the first three quarters of 2025 [1] Group 2 - The national medical insurance catalog for 2025 will officially be implemented starting January 1, 2026 [1]